144 related articles for article (PubMed ID: 27708434)
1. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations.
Park S; Lee J; Kim YH; Park J; Shin JW; Nam S
Sci Rep; 2016 Oct; 6():34822. PubMed ID: 27708434
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
3. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
4. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
Moon S; Balch C; Park S; Lee J; Sung J; Nam S
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
[TBL] [Abstract][Full Text] [Related]
5. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.
Tahara T; Shibata T; Okamoto Y; Yamazaki J; Kawamura T; Horiguchi N; Okubo M; Nakano N; Ishizuka T; Nagasaka M; Nakagawa Y; Ohmiya N
Oncotarget; 2016 Jul; 7(27):42252-60. PubMed ID: 27323394
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
7. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.
Fischer NW; Prodeus A; Gariépy J
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089713
[TBL] [Abstract][Full Text] [Related]
8. P53 deregulation in Epstein-Barr virus-associated gastric cancer.
Ribeiro J; Malta M; Galaghar A; Silva F; Afonso LP; Medeiros R; Sousa H
Cancer Lett; 2017 Sep; 404():37-43. PubMed ID: 28729047
[TBL] [Abstract][Full Text] [Related]
9. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
10. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
Biterge Süt B
Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
[TBL] [Abstract][Full Text] [Related]
11. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
Yao J; You Q; Zhang X; Zhang Y; Xu J; Zhao X; Li J; Wang X; Gong Z; Zhang D; Wang W
Clin Genet; 2023 Feb; 103(2):200-208. PubMed ID: 36346122
[TBL] [Abstract][Full Text] [Related]
13. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.
Kohno Y; Yamamoto H; Hirahashi M; Kumagae Y; Nakamura M; Oki E; Oda Y
Hum Pathol; 2016 Jun; 52():145-52. PubMed ID: 26980051
[TBL] [Abstract][Full Text] [Related]
14. Role of p53 in the progression of gastric cancer.
Busuttil RA; Zapparoli GV; Haupt S; Fennell C; Wong SQ; Pang JM; Takeno EA; Mitchell C; Di Costanzo N; Fox S; Haupt Y; Dobrovic A; Boussioutas A
Oncotarget; 2014 Dec; 5(23):12016-26. PubMed ID: 25427447
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathology of gastric carcinoma.
Jang BG; Kim WH
Pathobiology; 2011; 78(6):302-10. PubMed ID: 22104201
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours.
Mermejo LM; Leal LF; Colli LM; Fragoso MC; Latronico AC; Tone LG; Scrideli CA; Tucci S; Martinelli CE; Yunes JA; Mastellaro MJ; Seidinger AL; Brandalise SR; Moreira AC; Ramalho LN; Antonini SR; Castro M
Clin Endocrinol (Oxf); 2014 Oct; 81(4):503-10. PubMed ID: 24717047
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection.
Shimizu T; Marusawa H; Matsumoto Y; Inuzuka T; Ikeda A; Fujii Y; Minamiguchi S; Miyamoto S; Kou T; Sakai Y; Crabtree JE; Chiba T
Gastroenterology; 2014 Aug; 147(2):407-17.e3. PubMed ID: 24786892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
